Wieringa Frank T
UMR-204 Nutripass, Institut de Recherche pour le Développement, IRD/UM/SupAgro, 911 Av d'Agropolis, Montpellier, France.
BMC Med. 2017 May 11;15(1):99. doi: 10.1186/s12916-017-0867-8.
In developing countries, anemia and iron deficiency in early childhood are two highly prevalent public health problems. Providing caregivers with a powder containing multiple vitamins and minerals (also known as micronutrient powder or MNP) as a food supplement is a widely used strategy to combat these problems. However, concerns exist around MNP programs with regards to effectiveness and potential negative impact on diarrheal disease prevalence and gut flora. Teshome et al. (BMC Medicine 15:89, 2017) recently tested a MNP with a new iron formulation, iron-EDTA, which has a potentially higher bioavailability and thus requires a lower iron content. Nevertheless, neither the new formulation nor the standard formulation decreased anemia prevalence as compared to a control MNP without iron. However, in all groups, anemia prevalence was reduced after 30 days of intervention, and iron deficiency prevalence was significantly lower in children receiving iron-EDTA, showing that the new formulation holds promise. More research is needed to verify whether the lower iron content of these MNPs can also reduce the prevalence of associated side effects.Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0839-z .
在发展中国家,幼儿期贫血和缺铁是两个极为普遍的公共卫生问题。向照料者提供一种含有多种维生素和矿物质的粉末(也称为微量营养素粉或MNP)作为食品补充剂,是应对这些问题的一种广泛使用的策略。然而,对于MNP项目在有效性以及对腹泻病患病率和肠道菌群的潜在负面影响方面存在担忧。特肖梅等人(《BMC医学》15:89,2017年)最近对一种含有新铁制剂乙二胺四乙酸铁(iron-EDTA)的MNP进行了测试,该制剂可能具有更高的生物利用度,因此所需铁含量较低。然而,与不含铁的对照MNP相比,新制剂和标准制剂均未降低贫血患病率。不过,在所有组中,干预30天后贫血患病率均有所降低,并且接受乙二胺四乙酸铁的儿童缺铁患病率显著更低,这表明新制剂具有前景。需要更多研究来验证这些MNP较低的铁含量是否也能降低相关副作用的患病率。请参阅相关文章:https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0839-z 。